Ernexa Therapeutics Shares Surge After Firm Sets IND Submission Timeline for ERNA-101
Ernexa Therapeutics reported completion of manufacturing process development and the start of GMP production for its lead allogeneic cell therapy candidate ERNA-101, and announced plans to submit an Investigational New Drug application in the third quarter of 2026. The update, which included preclinical efficacy data and a completed $10.5 million f…